A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
- PMID: 27094310
- PMCID: PMC5403851
- DOI: 10.1007/s10238-016-0417-2
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
Abstract
The thrombin generation potential is an in vitro measure for the capacity of an individual to generate thrombin and recognized as a reflection of a hypo- or hypercoagulable status. Measurement of the in vivo thrombin activity, however, may be of clinical significance. We evaluated a new assay for in vivo thrombin activity and compared it to the in vitro thrombin generation potential in patients with hemophilia A (N = 15), oral anticoagulation for atrial fibrillation (AF) (N = 20), subjects with active cancer (N = 21), and healthy volunteers (N = 10). Thrombin activity was measured with a commercially available oligonucleotide enzyme capture assay in argatroban-stabilized plasma samples. Thrombin generation potential was determined with a commercially available assay in citrated plasma. Thrombin activity was detected in 17 (30.4 %) patients (mean 0.30 mU/ml [SD 0.80]), and in 39 patients (69.6 %) no thrombin activity was present. In cancer patients, thrombin activity was detected in 11 patients (52 %) (range 0.14-5.00 mU/ml) and was particularly increased in 3 patients with vessel-invasive tumors (1.2, 1.5, and 5.0 mU/ml). In AF patients, thrombin activity was only measureable in two patients (10 %) (recent hematoma [0.4 mU/ml] and recent ischemic stroke [1.5 mU/ml]). Thrombin activity was detected in four patients (27 %) with hemophilia (range 0.29-1.75 mU/ml), all of whom had received a factor VIII infusion on the same day. Thrombin activity did not correlate with any of the parameters of the thrombin generation potential. Only patients in acute procoagulatory states or after clotting factor replacement had elevated in vivo thrombin activity, which was, however, unrelated to the in vitro thrombin generation potential.
Keywords: Blood coagulation tests; Hemophilia; Thrombin; Thrombophilia.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability.Haematologica. 2003 May;88(5):547-54. Haematologica. 2003. PMID: 12745274
-
The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53. doi: 10.1159/000073575. Pathophysiol Haemost Thromb. 2002. PMID: 13679651 Review.
-
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.Minerva Med. 1997 Dec;88(12):501-5. Minerva Med. 1997. PMID: 9540779
-
Ex vivo thrombin generation in patients with venous thromboembolic disease or atrial fibrillation on long-term oral anticoagulation.Clin Appl Thromb Hemost. 2010 Dec;16(6):614-21. doi: 10.1177/1076029610363128. Epub 2010 May 11. Clin Appl Thromb Hemost. 2010. PMID: 20460350
-
[Thrombinography: towards a globalization of coagulation tests].Rev Med Liege. 2009 Apr;64(4):199-203. Rev Med Liege. 2009. PMID: 19514539 Review. French.
Cited by
-
Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model.Front Cardiovasc Med. 2021 Jul 2;8:690476. doi: 10.3389/fcvm.2021.690476. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34307502 Free PMC article.
-
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.Thromb Res. 2021 May;201:50-59. doi: 10.1016/j.thromres.2021.02.007. Epub 2021 Feb 16. Thromb Res. 2021. PMID: 33636573 Free PMC article.
-
Increased activity of procoagulant factors in patients with small cell lung cancer.PLoS One. 2021 Jul 21;16(7):e0253613. doi: 10.1371/journal.pone.0253613. eCollection 2021. PLoS One. 2021. PMID: 34288927 Free PMC article.
-
Aptamers in the Therapeutics and Diagnostics Pipelines.Theranostics. 2018 Jul 1;8(15):4016-4032. doi: 10.7150/thno.25958. eCollection 2018. Theranostics. 2018. PMID: 30128033 Free PMC article. Review.
-
Simple Methods and Rational Design for Enhancing Aptamer Sensitivity and Specificity.Front Mol Biosci. 2018 May 14;5:41. doi: 10.3389/fmolb.2018.00041. eCollection 2018. Front Mol Biosci. 2018. PMID: 29868605 Free PMC article.
References
-
- Hemker HC, Al Dieri R, de Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–561. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials